Biovail

ArriVent Appoints Kristine Peterson to its Board of Directors

Retrieved on: 
Lundi, avril 22, 2024
University, Cancer, Biovail, M.B.A, Amarin Corporation, Johnson & Johnson, Therapy, Senior, Bristol Myers Squibb, Patient, ImmunoGen, Champaign–Urbana metropolitan area, Lung cancer, Management

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors.

Key Points: 
  • NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors.
  • Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals.
  • “We are thrilled for Kris to join our Board of Directors at such an important time for ArriVent, as we advance the development of firmonertinib in multiple non-small cell lung cancer (“NSCLC”) indications,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent.
  • Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

Retrieved on: 
Lundi, octobre 18, 2021
Biotechnology, Pharmaceutical, Health, Program, Neurology, OAB, AstraZeneca, FDA, University, Overactive bladder, Therapy, Sarepta Therapeutics, Auburn University, NYSE, Patient, Intellectual property, VideoRay UROVs, Western University, Patent, Urinary incontinence, Uterine fibroid, Allergan, Brandman University, Man, Vibegron, Sumitomo Dainippon Pharma, Public relations, Biology, Chan, Bausch Health, MBA, Urologic disease, Industry, Bachelor of Science in Human Biology, Adult, Bachelor of Arts in Applied Psychology, Marketing, News, University of Victoria, Private practice, Biovail, University of Bologna, Management, Pharmaceutical industry, Fine chemical, Urovant Sciences, Sumitovant Biopharma Ltd., Sumitomo Dainippon Pharma Co., Ltd., UROVANT SCIENCES, SUMITOVANT BIOPHARMA LTD., SUMITOMO DAINIPPON PHARMA CO., LTD.

Genatossio, Darden Powell and Niemaszek join the Urovant Sciences executive leadership team and report to Urovant Sciences President and Chief Executive Officer James Robinson.

Key Points: 
  • Genatossio, Darden Powell and Niemaszek join the Urovant Sciences executive leadership team and report to Urovant Sciences President and Chief Executive Officer James Robinson.
  • I am very pleased to welcome Laura Genatossio to Urovant Sciences to lead our companys ambitious plans to expand our corporate presence in Europe.
  • This is an exciting time for all of us at Urovant Sciences, and our newly appointed senior leadership team members at Urovant will help drive our companys growth and evolution so that we may bring medical breakthroughs to more patients around the world.
  • Darden Powell will be responsible for leading the Urovant Sciences internal and external corporate communications programs and serves as a member of the Urovant executive leadership team.

aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs

Retrieved on: 
Mercredi, octobre 6, 2021
Biotechnology, Goal, RNA transfection, Negotiation, Employment, Annual report, CMC, Private Securities Litigation Reform Act, LIFE, FDA, Cancer, ATyr Pharma, Regulatory affairs, Sarcoidosis, Biovail, Compliance, Biology, Immunotherapy, Quality, Hypoparathyroidism, Growth, SAN, PTH, Forest Laboratories, Risk, COVID-19, IND, Research, Drug development, Massachusetts Institute of Technology, Forward-looking statement, Shire (pharmaceutical company), NPS, Nasdaq, SEC, Massachusetts, GLOBE, Medical device, Pharmaceutical industry

Prior to joining aTyr, Dr. Ashworth was Vice President, Regulatory Affairs, Quality and CMC at OncoSec Medical, Inc., where he developed and executed the regulatory strategy for novel immunotherapy products for cancer.

Key Points: 
  • Prior to joining aTyr, Dr. Ashworth was Vice President, Regulatory Affairs, Quality and CMC at OncoSec Medical, Inc., where he developed and executed the regulatory strategy for novel immunotherapy products for cancer.
  • Prior to that, he was Vice President, Regulatory Affairs, Quality and Compliance for Advaxis, Inc., where he developed and executed the global regulatory strategy for the companys immunotherapy platform.
  • As Vice President, Global Regulatory Affairs at NPS Pharmaceuticals, he was instrumental in negotiating the approval of NATPARA (PTH) for hypoparathyroidism.
  • When he was Vice President, Regulatory Affairs at Otsuka Pharmaceutical Development, Inc., he executed the regulatory strategy for ABILIFY, the companys flagship product.

Cipher Pharmaceuticals Appoints New Chief Financial Officer

Retrieved on: 
Jeudi, juillet 2, 2020
Biovail, Langille

OAKVILLE, ON, July 2, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer (CFO), he will succeed Interim CFO Nadine Jutlah.

Key Points: 
  • OAKVILLE, ON, July 2, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer (CFO), he will succeed Interim CFO Nadine Jutlah.
  • Mr. Langille has held senior roles at Tribute Pharmaceuticals, ViRexx Medical Corp, Zimmer Holdings, Verum Pharmaceuticals and Biovail Corporation.
  • "We are excited to welcome Scott to Cipher," said Mr. Craig Mull, Interim CEO.
  • Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.

Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs

Retrieved on: 
Mercredi, juin 6, 2018
Health, Biovail, Sanofi, Pharmaceutical industry in China, Economy of France

MISSISSAUGA, ON, June 6, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has joined the Company in the position of Vice President, Scientific and Medical Affairs.

Key Points: 
  • MISSISSAUGA, ON, June 6, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has joined the Company in the position of Vice President, Scientific and Medical Affairs.
  • Previously, Dr. Gajewczyk spent almost ten years at Biovail Corporation in several senior positions, including Senior Director, Medical & Scientific Affairs, leading the scientific aspects of corporate development transactions.
  • Prior to focusing on medical and scientific affairs, she spent 12 years in pharmaceutical R&D at Sanofi Pasteur where she developed numerous patents and conducted IND-enabling studies for novel therapeutics.
  • "We are pleased to welcome Diane to the leadership team at Cipher," said Robert Tessarolo, President and CEO of Cipher.